SEARCH

SEARCH BY CITATION

References

  • 1
    Martin P, Friedman LS. Chronic viral hepatitis and the management of chronic renal failure. Kidney Int 1995; 47:12311241.MEDLINE
  • 2
    Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244:362364.MEDLINE
  • 3
    Fabrizi F, Martin P, Lunghi G, Ponticelli C. Nosocomial transmission of hepatitis C virus infection in hemodialysis patients: clinical perspectives. Int J Artif Organs 2000; 23:805816.MEDLINE
  • 4
    Bukh J, Wantzin P, Krogsgaard K, Knudsen F, Purcell RH, Miller RH, and The Copenhagen Dialysis HCV Study Group. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: failure of commercially available antibody tests to identify a significant number of patients with HCV infection. J Infect Dis 1993; 168:13431348.MEDLINE
  • 5
    Dalekos GN, Boumba DS, Katopodis K, Zervou E, Sferopoulos G, Elisaf M, Tsianos ET, et al. Absence of HCV viraemia in anti-HCV negative haemodialysis patients. Nephrol Dial Transplant 1998; 13:18041806.MEDLINE
  • 6
    Schneeberger PM, Keur I, Van der Vliet W, Van Hoek K, Boswijk H, Van Loon AM, Van Dijk WC, et al. Hepatitis C virus infection in dialysis centers in The Netherlands: a national survey by serological and molecular methods. J Clin Microbiol 1998; 36:17111715.MEDLINE
  • 7
    Donahue G, Munoz A, Ness PM, Yawn DEB, Ham DH, Reitz BA, Nelson KE. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992; 327:364373.
  • 8
    Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. Morb Mort Weekly Rep 2001; 50(RR-5):143.
  • 9
    World Health Organization. Hepatitis C: global prevalence. Weekly Epidemiol Rec. No. 46, 1997; 341348.
  • 10
    Weston SR, Martin P. Serological and molecular testing in viral hepatitis: an update. Can J Gastroenterol 2001; 15:177184.MEDLINE
  • 11
    Okuda K, Hayashi J, Yokozeki K, Irie Y. Destruction of hepatitis C virus particles by hemodialysis [Letter]. Lancet 1996; 347:909910.MEDLINE
  • 12
    Furusyo N, Hayashi J, Kakuda K, Ariyama I, Kanamoto-Tanaka Y, Shimizu C, Etoh Y, et al. Acute hepatitis C among Japanese hemodialysis patients: a prospective 9-year study. Am J Gastroenterol 2001; 96:15931600.
    Direct Link:
  • 13
    Fabrizi F, Martin P, Dixit V, Brezina M, Cole MJ, Gerosa S, Vinson S, et al. Acquisition of hepatitis C virus in hemodialysis patients: a prospective study by branched DNA signal amplification assay. Am J Kidney Dis 1998; 31:647654.MEDLINE
  • 14
    Pujol H, Ponce IG, Lema MG, Capriles F, Devesa M, Sirit F, Salazar M, et al. High incidence of hepatitis C virus infection in hemodialysis patients in units with high prevalence. J Clin Microbiol 1996; 34:16331636.MEDLINE
  • 15
    Chan TM, Lok ASF, Cheng IKP. Hepatitis C infection among dialysis patients: a comparison between patients on maintenance hemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1991; 6:944947.MEDLINE
  • 16
    Gilli P, Moretti M, Soffritti S, Marchi N, Malacarne F, Bedani PL, De Paoli Vitali E, et al. Non-A, non-B hepatitis and anti-HCV antibodies in dialysis patients. Int J Artif Organs 1990; 13:737741.MEDLINE
  • 17
    Fabrizi F, Martin P, Quan S, Dixit V, Brezina M, Conrad A, Polito A, et al. Serotyping strip immunoblot assay for assessing hepatitis C virus strains in dialysis patients. Am J Kidney Dis 2000; 35:832838.MEDLINE
  • 18
    Lombardi M, Cerrai T, Geatti S, Negroni S, Pertusini L, Pegoraro M, Di Lullo G. Results of a national epidemiological investigation of HCV infection among dialysis patients (Survey by the Italian Branch of EDTNA-ERCA). J Nephrol 1999; 12:322327.MEDLINE
  • 19
    Hung KY, Chen WY, Yang CS, Lee SH, Wu DJ. Hepatitis B and C in hemodialysis patients. Dial Transplant 1995; 24:135139.
  • 20
    dos Santos JP, Loureiro A, Cendoroglo Neto V, Pereira BJG. Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units. Nephrol Dial Transplant 1996; 11:20172022.MEDLINE
  • 21
    Simon P, Courouce' AM, Lemarrec N, Trepo C, Ducamp S. A twelve year natural history of hepatitis C virus infection in hemodialyzed patients. Kidney Int 1994; 46:504511.MEDLINE
  • 22
    Le Pogam S, Le Chapois D, Christen R, Dubois F, Barin F, Goudeau A. Hepatitis C in a hemodialysis unit: molecular evidence for nosocomial transmission. J Clin Microbiol 1998; 36:30403043.MEDLINE
  • 23
    Jadoul M, Cornu C, van Ypersele de Strihou C, and The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian multicenter study. Kidney Int 1998; 53:10221025.MEDLINE
  • 24
    Okuda KH, Hayashi H, Kobayashi S, Irie Y. Mode of hepatitis C infection not associated with blood transfusions among chronic hemodialysis patients. J Hepatol 1995; 23:2831.MEDLINE
  • 25
    Arenas DJ, Paya S, Gonzalez C, Rivera F, Enriquez R. Isolation of HCV patient is efficient in reducing the annual incidence of HCV infection, but is it really necessary? [Letter]. Nephrol Dial Transplant 1999; 14:13371339.
  • 26
    Djordjevic V, Stojanovic K, Stojanovic M, Stefanovic V. Prevention of nosocomial transmission of hepatitis C infection in a hemodialysis unit. A prospective study. Int J Artif Organs 2000; 23:181188.MEDLINE
  • 27
    Marcelli D, Stanhard D, Conte F, Held PJ, Locatelli F, Port FK. ESRD patient mortality with adjustement for comorbid conditions in Lombardy (Italy) versus the United States. Kidney Int 1996; 50:10131018.MEDLINE
  • 28
    Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354:9399.MEDLINE
  • 29
    Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000; 11:18961902.MEDLINE
  • 30
    Knoll GA, Tankerseley MR, Lee JY, Julian BA, Curtis J. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis 1997; 29:608614.MEDLINE
  • 31
    Wolfe RA, Ashby VB, Milford EL, Akinlolu O, Ettenger RE, Agodoa LYC, Held PJ, Port FK. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341:17251730.MEDLINE
  • 32
    Pereira BJG, Natov SN, Bouthot BA, Murthy BVR, Ruthazer R, Schmid CH, Levey AS, and the New England Organ Bank Hepatitis C Study Group. Effect of hepatitis C infection and renal transplantation on survival in end-stage renal disease. Kidney Int 1998; 53:13741381.MEDLINE
  • 33
    Martin P, Carter D, Fabrizi F, Dixit V, Conrad AJ, Artinian L, Peacock V, et al. Histopathological features of hepatitis C in renal transplant candidates. Transplantation 2000; 69:14791484.MEDLINE
  • 34
    Sterling RK, Sanyal AJ, Luketic VA, Stravitz RT, King AL, Post AB, Mills SA, et al. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation. Am J Gastroenterol 1999; 94; 35763582.MEDLINE
    Direct Link:
  • 35
    Rao KV, Anderson RW, Kasiske BL, Dahe RC. Value of liver biopsy in the evaluation and management of chronic liver disease in renal transplant recipients. Am J Med 1993; 94:241250.MEDLINE
  • 36
    Vosnides GG. Hepatitis C in renal transplantation. Kidney Int 1997; 52:843861.MEDLINE
  • 37
    Izopet J, Rostaing L, Sandres K, Cisterne JM, Pasquier C, Rumeau JL, Duffault M, et al. Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. J Infect Dis 2000; 181:852858.MEDLINE
  • 38
    Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29:257263.MEDLINE
  • 39
    Hanafusa T, Ichikawa Y, Kishikawa H, Kyo M, Fukunishi T, Kokado Y, Okuyama A, et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998; 66:471476.MEDLINE
  • 40
    Berthoux F. Hepatitis C virus infection and disease in renal transplantation. Nephron 1995; 71:386394.MEDLINE
  • 41
    Zucker K, Cirocco R, Roth D, Olson H, Burke GU, Nery J, Esquenazi V, et al. Depletion of hepatitis C virus from procured kidneys using pulsatile perfusion preservation. Transplantation 1994; 57:832840.MEDLINE
  • 42
    Morales JM, Campistol JM, Castellano G, Andres A, Colina F, Fuertes A, Ercilla G, et al. Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV. Kidney Int 1995; 47:236240.MEDLINE
  • 43
    Widell A, Mansson S, Persson NH, Thysell H, Hermodsson S, Blohme I. Hepatitis C superinfection in hepatitis C virus (HCV) infected patients transplanted with an HCV-infected kidney. Transplantation 1995; 60:642647.MEDLINE
  • 44
    Ali MK, Light JA, Barhyte DY, Sasaki TM, Currier CB, Grandas O, Fowlkes D. Donor hepatitis virus status does not adversely affect short-term outcomes in HCV positive recipients in renal transplantation. Transplantation 1998; 66:16941697.MEDLINE
  • 45
    Huraib S, Iqbal A, Tanimu D, Abdullah A. Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. Am J Nephrol 2001; 21:435440.MEDLINE
  • 46
    Rostaing L, Chatelut E, Payen JL, Thalamas C, Ton-That H, Pascal JP, Durand D, et al. Pharmacokinetics of alpha IFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998; 9:23442348.MEDLINE
  • 47
    Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection—a pilot study. J Viral Hep 2001; 8:287292.
  • 48
    Rostaing L. Treatment of hepatitis C virus infection after renal transplantation: new insights. Nephrol Dial Transplant 2000; 15(Suppl 8):7476.MEDLINE
  • 49
    Martin P, Mitra S, Farrington K, Martin NE, Modi MW. Pegylated (40KDA) interferon alfa-2a (Pegasys™) is unaffected by renal impairment [Abstract]. Hepatology 2000; 32(Part 2):842.MEDLINE
  • 50
    Kasiske BL, Cangro CB, Sundaram H, Hricik DE, Kerman RH, Roth D, Rush DN, et al. for the American Society of Transplantation. The evaluation of renal transplant candidates: clinical practices guidelines. Am J Transplant 2001; 2(Suppl 1):595.
  • 51
    Casanovas-Taltavull T, Baliellas C, Benasco C, Serrano T, Casanova A, Perez JL, Guerrero L, et al. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol 2001; 96:11701177.MEDLINE